Literature DB >> 12544809

Managing cystoid macular edema after cataract surgery.

Mark L Nelson1, Adam Martidis.   

Abstract

Cystoid macular edema (CME) is a common problem after cataract extraction. It can occur after uncomplicated surgery in patients with otherwise healthy eyes, after complicated surgery, or after surgery in patients with ocular diseases such as uveitis or diabetic retinopathy. Usually vision loss from cystoid macular edema is temporary and responds to treatment with topical anti-inflammatory medications. However, some cases respond poorly to conservative treatment and may develop permanent visual loss. A review of the medical literature was performed for all articles published in English between August 1, 2001 and July 31, 2002 on the topic of cystoid macular edema after cataract surgery. The authors selected nine articles that were most relevant to the practicing ophthalmologist for inclusion in this review. Topics of interest included vitreous loss, retained lens fragments, diabetes, uveitis, retinitis pigmentosa, ocular hypotensive lipids, internal limiting membrane peeling, and intravitreal triamcinolone injection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12544809     DOI: 10.1097/00055735-200302000-00007

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  23 in total

Review 1.  [Ocular side effects and complications of intravitreal triamcinolone acetonide injection].

Authors:  G B Jaissle; P Szurman; K U Bartz-Schmidt
Journal:  Ophthalmologe       Date:  2004-02       Impact factor: 1.059

2.  RECALCITRANT CYSTOID MACULAR EDEMA AFTER PARS PLANA VITRECTOMY.

Authors:  Mostafa R Alam; Cheryl A Arcinue; Nadia B Mendoza; William R Freeman
Journal:  Retina       Date:  2016-07       Impact factor: 4.256

3.  Which procedure has more effect on macular thickness: primary posterior continuous capsulorhexis (PPCC) combined with phacoemulsification or Nd:YAG laser capsulotomy?

Authors:  Necip Kara; Ahmet Taylan Yazici; Ercument Bozkurt; Yusuf Yildirim; Ahmet Demirok; Omer Faruk Yilmaz
Journal:  Int Ophthalmol       Date:  2011-08-14       Impact factor: 2.031

4.  Effect of nepafenac 0.1% on retinal thickness after cataract surgery in patients without risk factors for cystoid macular edema.

Authors:  Asena Keleş Şahin; Ahmet Şahap Kükner; Fatih Ulaş; Ümit Doğan
Journal:  Int J Ophthalmol       Date:  2020-12-18       Impact factor: 1.779

5.  Impact of tamsulosin exposure on late complications following cataract surgery: retrospective cohort study.

Authors:  Julio González-Martín-Moro; Julio José González-López; Fernando Gómez-Sanz; Jesús Zarallo-Gallardo; Rosario Cobo-Soriano
Journal:  Int Ophthalmol       Date:  2013-10-25       Impact factor: 2.031

6.  Illustrations as a patient education tool to improve recall of postoperative cataract medication regimens in the developing world.

Authors:  M Scott Hickman; William L White; W Abraham White
Journal:  Hawaii Med J       Date:  2010-09

7.  Management of nucleus loss into the vitreous: long term follow up in 63 patients.

Authors:  Pedro Romero-Aroca; Juan Fernández-Ballart; Isabel Méndez-Marín; Merce Salvat-Serra; Marc Baget-Bernaldiz; Jose A Buil-Calvo
Journal:  Clin Ophthalmol       Date:  2007-12

8.  Diclofenac prevents temporal increase of intraocular pressure after uneventful cataract surgery with longer operation time.

Authors:  Masahiko Shimura; Toru Nakazawa; Kanako Yasuda; Takashi Shiono; Kohji Nishida
Journal:  Clin Ophthalmol       Date:  2009-06-02

9.  Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography.

Authors:  Marie-Lyne Bélair; Stephen J Kim; Jennifer E Thorne; James P Dunn; Sanjay R Kedhar; Diane M Brown; Douglas A Jabs
Journal:  Am J Ophthalmol       Date:  2009-04-29       Impact factor: 5.258

Review 10.  [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].

Authors:  J B Jonas; I Kreissig; B Kamppeter; R F Degenring
Journal:  Ophthalmologe       Date:  2004-02       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.